Home Featured Page 230

Featured

Latest

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Martha Hammel and Tasia Poinsatte – Aspen Psychedelic Symposium

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors...

MINDCURE Announces Commencement of Trading on the OTCQX Best Market

Psyence Group and Pure Extracts Finalize “Pure Psyence,” A Joint Venture...

PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors

PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as...

Mindset Pharma Expands Pipeline: Identifies Additional Next Generation 5-MeO-DMT-Inspired Lead Candidates

Red Light Holland: Initial Results From Red Light Oregon Market Research...

Psychedelics and Pregnancy: A Look Into the Safety, Research and Legality

MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan...

MDMA: A Catalyst for ED-PTSD Treatment

EDITOR PICKS

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive...

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.